Transcatheter aortic valve replacement (TAVR) was associated with lower in-hospital mortality and significantly fewer respiratory complications than surgery for patients with chronic obstructive pulmonary disease (COPD), according to study published April 1 in the Journal of the American Heart Association.

Already approved for the purpose its name implies, the Gore Cardioform septal occluder has also received the FDA’s OK for patent foramen ovale (PFO) closure to prevent recurrent ischemic stroke.

Women whose babies are born with congenital heart defects may have a higher risk of cardiovascular disease themselves, according to a study of more than one million women published online April 2 in Circulation.

Sutureless valves have recently been developed to streamline surgical aortic valve replacement (SAVR) procedures, with the hope that shorter operations lead to better outcomes. But a new study in the Journal of the American College of Cardiology suggests quicker is not always better.

Bioprosthetic heart valves used in surgical aortic valve replacement (SAVR) procedures in the early 2000s demonstrated “satisfactory” durability, according to a single-center study published in the Journal of the American College of Cardiology.

A high dose of oral ibuprofen appeared to be the best option for closing patent ductus arteriosus (PDA) in a meta-analysis of 4,802 preterm infants, researchers reported in JAMA.

Edwards Lifesciences notched a victory in its ongoing dispute with Boston Scientific concerning transcatheter aortic valve replacement (TAVR) patents.

Occluder devices to combat congenital structural heart defects designed by the indigenous Aymara women suggest “excellent” clinical outcomes and have been approved by regulatory agencies in Canada, South America and the European Union.